Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

10.1016/s0140-6736(14)60845-x ◽

2014 ◽

Vol 384 (9944) ◽

pp. 665-673 ◽

Author(s):

Edward B Garon ◽

Tudor-Eliade Ciuleanu ◽

Oscar Arrieta ◽

Kumar Prabhash ◽

Konstantinos N Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.lba8006 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. LBA8006-LBA8006 ◽

Author(s):

Maurice Perol ◽

Tudor-Eliade Ciuleanu ◽

Oscar Arrieta ◽

Kumar Prabhash ◽

Konstantinos N. Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

Cancer Research and Treatment ◽

10.4143/crt.2015.401 ◽

2016 ◽

Vol 48 (4) ◽

pp. 1177-1186 ◽

Author(s):

Keunchil Park ◽

Joo-Hang Kim ◽

Eun Kyung Cho ◽

Jin-Hyoung Kang ◽

Jin-Yuan Shih ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Subgroup Analysis ◽

Stage Iv ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-3560-5 ◽

2018 ◽

Vol 82 (1) ◽

pp. 77-86 ◽

Author(s):

Egbert F. Smit ◽

Edward B. Garon ◽

Martin Reck ◽

Federico Cappuzzo ◽

Paolo Bidoli ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Response Relationship ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Exposure Response

Download Full-text

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(10)70132-7 ◽

2010 ◽

Vol 11 (7) ◽

pp. 619-626 ◽

Author(s):

Roy S Herbst ◽

Yan Sun ◽

Wilfried EE Eberhardt ◽

Paul Germonpré ◽

Nagahiro Saijo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology

Annals of Oncology ◽

10.1093/annonc/mdv343.04 ◽

2015 ◽

Vol 26 ◽

pp. vi74 ◽

Author(s):

P. Bidoli ◽

F. Cappuzzo ◽

A. Favaretto ◽

O. Alabiso ◽

M. Tiseo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Subgroup Analysis ◽

Stage Iv ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.18s.cra8003 ◽

2009 ◽

Vol 27 (18S) ◽

pp. CRA8003-CRA8003 ◽

Author(s):

R. S. Herbst ◽

Y. Sun ◽

S. Korfee ◽

P. Germonpré ◽

N. Saijo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Trial

Download Full-text

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Lung Cancer ◽

10.1016/j.lungcan.2016.06.019 ◽

2016 ◽

Vol 99 ◽

pp. 94-101 ◽

Author(s):

Egbert F. Smit ◽

Yi-Long Wu ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2017.07.038 ◽

2017 ◽

Vol 112 ◽

pp. 181-187 ◽

Author(s):

Martin Reck ◽

Luis Paz-Ares ◽

Paolo Bidoli ◽

Federico Cappuzzo ◽

Shaker Dakhil ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Phase Iii ◽

Refractory Disease ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

Clinical Lung Cancer ◽

10.1016/j.cllc.2012.06.007 ◽

2012 ◽

Vol 13 (6) ◽

pp. 505-509 ◽

Author(s):

Edward B. Garon ◽

Dachuang Cao ◽

Ekaterine Alexandris ◽

William J. John ◽

Sergey Yurasov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Study Design ◽

Stage Iv ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text